PLX receives FDA approval. CHTP Northera update

May 01, 2012 No Comments by

Pfizer Inc.(NYSE:PFE) and Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX) announced today that the FDA has approved ELELYSO (taliglucerase alfa) for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease. The label is available HERE.

Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today gave an update on its Complete Response Letter (CRL) received in March 2012 for Northera (droxidopa). A meeting with the FDA is scheduled to take place in May with formal meeting minutes likely by the end of May. At this time the company will host a conference call to discuss the path ahead for Northera.

Daily News

About the author

Currently residing in New Zealand and employed in the education industry, Mr. A. Burden holds a M.Com in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.
No Responses to “PLX receives FDA approval. CHTP Northera update”

Leave a Reply